OBJECTIVE: The selective in vivo localization of antibody derivatives in atherosclerotic plaques may open novel diagnostic and therapeutic applications. Here, we present a comparative in vivo localization analysis of eight radioiodinated human monoclonal antibodies in apolipoprotein E-deficient (ApoE(-/-)) mice. METHODS: Animals were fed with a cholesterol-rich diet, followed by harvesting of the aorta 24h after intravenous antibody injection and investigated by autoradiographic analysis. Localization of F8 antibody on atherosclerotic plaque structures was further studied in three-color fluorescence microscopy. RESULTS: The study revealed that the F8 antibody, specific to the alternatively spliced EDA domain of fibronectin, exhibited the highest plaque-targeting potential among the antibodies analyzed in this study, with an ability to preferentially localize to all plaques within the aorta. Targeting results were confirmed by injection of fluorescein-labeled F8 antibody, followed by three-color fluorescence microscopy analysis. CONCLUSION: These findings open novel biomolecular avenues for the in vivo imaging of atherosclerotic plaques and for pharmacodelivery applications, since F8 had previously been reported by our group to strongly stain atherosclerotic plaques in human carotid arteries.
OBJECTIVE: The selective in vivo localization of antibody derivatives in atherosclerotic plaques may open novel diagnostic and therapeutic applications. Here, we present a comparative in vivo localization analysis of eight radioiodinated human monoclonal antibodies in apolipoprotein E-deficient (ApoE(-/-)) mice. METHODS: Animals were fed with a cholesterol-rich diet, followed by harvesting of the aorta 24h after intravenous antibody injection and investigated by autoradiographic analysis. Localization of F8 antibody on atherosclerotic plaque structures was further studied in three-color fluorescence microscopy. RESULTS: The study revealed that the F8 antibody, specific to the alternatively spliced EDA domain of fibronectin, exhibited the highest plaque-targeting potential among the antibodies analyzed in this study, with an ability to preferentially localize to all plaques within the aorta. Targeting results were confirmed by injection of fluorescein-labeled F8 antibody, followed by three-color fluorescence microscopy analysis. CONCLUSION: These findings open novel biomolecular avenues for the in vivo imaging of atherosclerotic plaques and for pharmacodelivery applications, since F8 had previously been reported by our group to strongly stain atherosclerotic plaques in human carotid arteries.
Authors: Tobias A Fuchs; Michael Fiechter; Cathérine Gebhard; Julia Stehli; Jelena R Ghadri; Egle Kazakauskaite; Bernhard A Herzog; Lars Husmann; Oliver Gaemperli; Philipp A Kaufmann Journal: Int J Cardiovasc Imaging Date: 2012-10-02 Impact factor: 2.357
Authors: Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner Journal: J Mol Histol Date: 2014-05-03 Impact factor: 2.611
Authors: Anders Orbom; Bo Jansson; Alexandru Schiopu; Susan Evans-Axelsson; Jan Nilsson; Gunilla Nordin Fredrikson; Sven-Erik Strand Journal: Am J Nucl Med Mol Imaging Date: 2014-03-20
Authors: Peter-Christian Klöhn; Ulrich Wuellner; Nora Zizlsperger; Yu Zhou; Daniel Tavares; Sven Berger; Kirstin A Zettlitz; Gabriele Proetzel; May Yong; Richard H J Begent; Janice M Reichert Journal: MAbs Date: 2013 Mar-Apr Impact factor: 5.857